Longevity learning resources
Clinician testing reference and a plain-language guide to additional blood tests, with downloadable PDFs.
Beyond the Standard Panel: A Testing Reference: *Resource page and one-page downloadable. Audience: doctors, nurse prescribers, aesthetic practitioners, nutritionists and coaches working with clinicians who want to practise further upstream than a standard panel allows.*
Most clinicians are trained to test to a threshold: the point at which a result becomes a diagnosis. That is the right instinct for acute care. For longevity-focused practice it misses the window where intervention matters most, the years before a standard result moves out of range, when the underlying process is already active and still reversible.
| Area | Standard test | Order instead / alongside | Why it matters |
|---|---|---|---|
| Diabetes risk | HbA1c, fasting glucose | Fasting insulin + HOMA-IR | Raised fasting insulin with normal glucose is the window: years of compensation before glucose moves |
| Cardiovascular risk | Standard lipid panel | ApoB; Lp(a) (once) | ApoB tracks particle number, not just cholesterol content. Lp(a) is largely genetic: test once, it informs risk stratification rather than a repeat-monitoring plan |
| Inflammation | None routine | hs-CRP | Predicts cardiovascular events independent of cholesterol; cheap and on most lab menus |
| Thyroid | TSH alone | Free T3, free T4, TPO/TgAb antibodies | Antibodies can flag autoimmune thyroid disease years before TSH drifts |
| Liver | ALT/AST | FIB-4 (calculated from age, ALT, AST, platelets) | No new test: a calculation from values already on a standard panel, worth running routinely |
| Micronutrients | Usually none | Vitamin D, ferritin, homocysteine | A normal full blood count does not rule any of these out. Homocysteine is a risk marker (association), not a proven treatment target |
**Why this matters for your practice.** A client told "your bloods are normal" elsewhere who then gets a result from you that explains how they feel understands, for the first time, what you do differently. That is what turns a one-off booking into a returning client who refers others.
**Why a list of tests is not enough.** Knowing which markers to order is the easy part. The harder part is what to do with six results that each point in a slightly different direction for the same person: which is the driver, which are downstream, and which single intervention to prioritise first. That is a framework problem, not a testing problem.
**Where this fits.** The HSI Anti-Ageing & Longevity Medicine Certification teaches this in full: not just which tests to order, but the Healthspan Model and HSI Method for turning results into a coherent, personalised case.
**Sources**
- Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. *J Clin Invest* 2006. https://www.jci.org/articles/view/29103
- Sniderman AD et al. Meta-analysis of LDL-C, non-HDL-C and apoB as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes* 2011. https://www.ahajournals.org/doi/10.1161/circoutcomes.110.959247
- Lipoprotein(a): a genetically determined, causal and prevalent risk factor for atherosclerotic cardiovascular disease. AHA Scientific Statement. https://www.ahajournals.org/doi/10.1161/ATV.0000000000000147
- Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). *N Engl J Med* 2008. https://www.nejm.org/doi/full/10.1056/NEJMoa0807646
- Transitioning FIB-4 score: from fibrosis screening tool to key biomarker for clinical endpoints. *J Hepatol*. https://www.journal-of-hepatology.eu/article/S0168-8278(24)00353-2/fulltext
- Homocysteine as a risk factor for cardiovascular disease. *Swiss Med Wkly*. https://smw.ch/index.php/smw/article/download/672/669/1332 (association only; B-vitamin trials have had mixed cardiovascular results)
What Standard Testing Misses: *Lead-magnet page. Audience: the curious public and early-stage learners. Not a replacement for seeing your doctor.*
### Why standard testing stops where it does
Standard testing is built around diagnostic thresholds: the point where disease is present or close. That is a sensible design for finding disease. It is not designed to show the years of drift beforehand, because those earlier markers rarely change what a threshold-based pathway does next. Functional and longevity medicine works in that gap.
### Diabetes risk
**Standard test:** HbA1c or fasting glucose.
**What it misses:** by the time either rises above normal, the pancreas has usually been over-producing insulin to compensate for years. Insulin resistance is the early, silent phase.
**The earlier marker:** fasting insulin, and HOMA-IR calculated from fasting insulin and glucose. High fasting insulin with a still-normal glucose is the pattern standard testing is built to miss.
### Cardiovascular risk
**Standard test:** lipid panel (total cholesterol, LDL, HDL, triglycerides).
**What it misses:** LDL is a concentration, not a count. Two people can have the same LDL while one carries far more of the particles that drive plaque.
**The better markers:** ApoB, a direct count of those particles, predicts cardiovascular risk more strongly than LDL alone in head-to-head studies. Lp(a) is a separate, largely genetic risk factor that is not routinely tested; worth testing once.
### Inflammation
**Standard test:** nothing, routinely.
**What it misses:** chronic low-grade inflammation ("inflammaging") is one of the twelve recognised hallmarks of aging and an active driver of cardiovascular, metabolic and cognitive decline.
**The earlier marker:** high-sensitivity CRP (hs-CRP). Elevated hs-CRP has been shown to predict cardiovascular events independently of cholesterol.
### Thyroid function
**Standard test:** TSH alone.
**What it misses:** TSH is a pituitary signal, not a direct measure of the hormones doing the work. A normal TSH can sit alongside low free T3, or rising antibodies years before TSH moves.
**The fuller picture:** free T3, free T4 and antibodies (TPO, TgAb) alongside TSH.
### Liver health
**Standard test:** ALT and AST, flagged once clearly abnormal.
**What it misses:** fatty liver disease can be well underway with ALT and AST still in range.
**The earlier marker:** the FIB-4 score, calculated from age, ALT, AST and platelets, all already on a standard panel.
### Micronutrient status
**Standard test:** usually nothing unless there is a specific symptom.
**What it misses:** vitamin D, ferritin (iron stores) and homocysteine can sit outside optimal ranges for years while a full blood count looks unremarkable.
**The earlier marker:** test them directly. Homocysteine is a risk marker worth knowing, not a target proven to change outcomes on its own.
### How to use this with your own doctor
This is a conversation-opener, not a replacement for your GP: "My standard results are normal. What else is worth knowing before something shows up on that test?" Normal range is not the same as optimal, and the gap between them is where functional and longevity medicine does its work.
Explore the Diploma